Dong-A ST Signs Joint Research Agreement with CrystalPi

Based on an Intelligent Automated Drug Discovery Platform

Dong-A ST announced on August 20 that it has signed a joint research agreement with the AI drug discovery company CrystalPi for the development of therapeutics targeting immune and inflammatory diseases.

Dong-A ST

This agreement will be carried out based on CrystalPi's intelligent automated drug discovery platform, which integrates AI, quantum physics, and automated robotics technologies. The two companies plan to utilize the platform to identify new targets for immune and inflammatory diseases and to search for first-in-class and best-in-class candidate compounds.

CrystalPi's platform is known to dramatically accelerate drug development and expand the accessible chemical space by combining the speed and generative capabilities of AI with the precision of robot-based automated experiments. Through CrystalPi's platform, the companies plan to conduct deep learning-based molecular design, quantum physics and molecular dynamics simulations for drug-target interaction prediction, automated chemical synthesis, and experimental validation of key pharmacological properties of candidate compounds.

Dong-A ST will participate in the entire research and development process, including the evaluation of candidate compound feasibility, verification of efficacy and safety, and the establishment of preclinical and clinical development strategies. The company also plans to review the potential for pipeline expansion and commercialization in the future.

CrystalPi was founded in 2015 by quantum physics experts from the Massachusetts Institute of Technology (MIT). The company has established partnerships with numerous global firms in the life sciences and advanced materials sectors and is actively collaborating with global pharmaceutical companies.

John Wang, Executive Vice President of Drug Development at CrystalPi, stated, "The combination of Dong-A ST's extensive expertise and CrystalPi's proven AI-robotics platform is a powerful synergy that can translate scientific innovation into competitive precision medicine. The two companies will rapidly identify and validate drug candidates across multiple modalities and deliver innovative therapies to global patients, creating new market opportunities."

Park Jaehong, Head of Research and Development at Dong-A ST, said, "Dong-A ST is transitioning its R&D focus from small molecule drug development to targeted protein degraders (TPD), biopharmaceuticals, antibody-drug conjugates (ADC), and gene therapies. This collaboration will serve as a key catalyst in accelerating that transition. By leveraging the synergy with CrystalPi's AI platform, we will accelerate the development of next-generation therapies for immune and inflammatory diseases."

This content was produced with the assistance of AI translation services.